ENGN enGene Holdings Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Sep 8, 2026ENGN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
ENGN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ENGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 0.6 | · | 3.0 | Undervalued |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ENGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.0 | · | · | · | |
| Current Ratio (MRQ) | 10.2 | · | 9.0 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Sept. 30, 2026 | Sep 8, 2026 | $-0.47 | $-0.44 | -7.2% |
| June 30, 2026 | Jun 1, 2026 | $-0.43 | $-0.48 | 10.3% |
| March 31, 2026 | $-0.44 | $-0.57 | 22.9% | |
| Dec. 31, 2025 | $-0.73 | $-0.58 | -25.9% | |
| Sept. 30, 2025 | $-0.57 | $-0.51 | -11.5% | |
| June 30, 2025 | $-0.51 | $-0.51 | -0.37% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| R&D Expense | $20M | $6M | $4M | |
| SG&A Expense | $14M | $5M | $962.0K | |
| Operating Expenses | $34M | $11M | $5M | |
| Operating Income | $-34M | $-11M | $-5M | |
| Interest Expense | · | $563.0K | $1M | |
| Interest Income | $2M | $1M | $167.0K | |
| Other Non-op | $-45.0K | $-64.0K | $-285.0K | |
| Pretax Income | $-33M | $-11M | $-7M | |
| Income Tax | $0 | $-30.0K | $0 | |
| Net Income | $-33M | $-11M | $-7M | |
| EPS (Basic) | $-0.47 | $0.46 | $13.29 | |
| EPS (Diluted) | $-0.47 | $0.46 | $13.29 | |
| Shares (Basic) | 69,734,610 | 23,197,976 | 651,074 | |
| Shares (Diluted) | 69,734,610 | 23,197,976 | 651,074 | |
| EBITDA | $-34M | · | · |
Balance Sheet
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $41M | $86M | · | |
| Short-term Investments | $225M | · | · | |
| Prepaid Expense | $11M | $3M | · | |
| Current Assets | $278M | $90M | · | |
| PP&E (Net) | $2M | $993.0K | · | |
| PP&E (Gross) | $5M | $3M | · | |
| Accum. Depreciation | $3M | $2M | · | |
| Other Non-current Assets | $1M | $974.0K | · | |
| Total Assets | $288M | $93M | · | |
| Accounts Payable | $3M | $1M | · | |
| Short-term Debt | $199.0K | · | · | |
| Current Liabilities | $27M | $7M | · | |
| Capital Leases | $6M | $2M | · | |
| Total Liabilities | $58M | $31M | · | |
| Total Debt | $199.0K | · | · | |
| Common Stock | $632M | $259M | · | |
| Retained Earnings | $-465M | $-210M | · | |
| AOCI | $-1M | $-1M | · | |
| Stockholders' Equity | $230M | $62M | · | |
| Liabilities + Equity | $288M | $93M | · | |
| Shares Outstanding | 67,014,067 | 23,197,976 | · |
Cash Flow
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| D&A | $100.0K | $80.0K | $46.0K | |
| Stock-based Comp | $8M | $291.0K | $20.0K | |
| Operating Cash Flow | $-19M | $-7M | $-6M | |
| CapEx | $0 | $506.0K | $13.0K | |
| Investing Cash Flow | $30M | $-506.0K | $-13.0K | |
| Financing Cash Flow | $23.0K | $12M | $-10.0K | |
| Net Change in Cash | $11M | $4M | $-6M |
Profitability
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| ROA | -12.2% | · | · | |
| ROE | -15.1% | · | · | |
| ROIC | -14.8% | · | · |
Liquidity & Solvency
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| Current Ratio | 10.2 | · | · | |
| Quick Ratio | 9.8 | · | · | |
| Debt / Equity | 0.0 | · | · |
Per Share
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| Book Value / Share | $3.44 | · | · | |
| Cash / Share | $0.61 | · | · | |
| Dividend / Share | $0.00 | · | · | |
| Dividend Paid / Share | $0.00 | $0.00 | · | |
| EPS (TTM) | $0.27 | · | · |
Valuation (TTM)
| Metric | Trend | Q3 2026 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| Net Income TTM | $-130M | · | · | |
| Market Cap | $120M | · | · | |
| Enterprise Value | $-146M | · | · | |
| P/E | 6.6 | · | · | |
| P/B | 0.5 | · | · | |
| P / Tangible Book | 0.5 | · | · | |
| Earnings Yield | 15.1% | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 6 filers · $20.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 | 55 | 1 | 0 | · |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FCPM III SERVICES B.V. | $16,664,330 | 9,632,561 | 83.03% | Shares |
| Omega Fund Management, LLC | $1,516,098 | 876,357 | 7.55% | Shares |
| SR One Capital Management, LP | $1,293,607 | 747,750 | 6.45% | Shares |
| Quadrature Capital Ltd | $413,531 | 239,035 | 2.06% | Shares |
| TWO SIGMA ADVISERS, LP | $156,219 | 17,300 | 0.78% | Shares |
| OBSIDIAN CIO, LLC | $25,950 | 15,000 | 0.13% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Forbion Growth Sponsor FEAC I B.V., Forbion Growth Opportunities Fund I Cooperatief U.A., Forbion Growth Management B.V. ×2 filings | Nov. 1, 2024 | · | Initial filing | · | SEC |
| Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Québec), L.P., Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc., Peter van der Velden, Benjamin Rovinski, Daniel Hetu, Gerald Brunk, Vasco Larcina, Jacki Jenuth ×2 filings | Feb. 21, 2024 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 25 insiders · 14 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ronald Harold Wilfred Cooper | CEO & President | Jan. 30, 2026 A | 10,000 | 0 | 0 | $0 |
| Jason David Hanson | Chief Executive Officer | July 7, 2023 A | · | 0 | 0 | $0 |
| Ryan D. Daws | Chief Financial Officer | Jan. 30, 2026 A | · | 0 | 0 | $0 |
| Matthew Ross Boyd | Chief Regulatory Officer | Jan. 30, 2026 A | · | 0 | 0 | $0 |
| Joan Connolly | Chief Technology Officer | Jan. 30, 2026 A | · | 0 | 0 | $0 |
| Alexander Julian Nichols | Chief Strategy & Ops. Ofc | Jan. 30, 2026 A | · | 0 | 0 | $0 |
| Anthony Tzeyew Cheung | Chief Scientific Officer | Jan. 30, 2026 A | 102,873 | 0 | 0 | $0 |
| Lee Giguere | Chief Legal Ofc. and Corp Secy | Jan. 30, 2026 A | · | 0 | 0 | $0 |
| Jill Buck | Chief Development Officer | Jan. 30, 2026 A | · | 0 | 0 | $0 |
| Hussein Sweiti | Chief Medical Officer | Sept. 30, 2025 A | · | 0 | 0 | $0 |
| Amy Pott | Chief Global Comm. Ofc. | June 16, 2025 A | · | 0 | 0 | $0 |
| Raj Som Pruthi | Chief Medical Officer | Jan. 29, 2025 A | · | 0 | 0 | $0 |
| Richard Paul Bryce | Chief Medical Officer | Nov. 30, 2023 A | · | 0 | 0 | $0 |
| James Crowley Sullivan | Chief Scientific Officer | July 7, 2023 A | · | 0 | 0 | $0 |
| William Grossman | Director | July 8, 2025 A | · | 0 | 0 | $0 |
| Michael Thomas Heffernan | Director | July 8, 2025 A | · | 0 | 0 | $0 |
| Philip Astley-Sparke | Director | July 8, 2025 A | · | 0 | 0 | $0 |
| Wouter Joustra | Director | June 16, 2025 A | · | 0 | 0 | $0 |
| Jasper Bos | Director | June 16, 2025 A | · | 0 | 0 | $0 |
| Gerald A Brunk | Director | June 16, 2025 A | 238,851 | 0 | 0 | $0 |
| Richard M Glickman | Director | June 16, 2025 A | 24,675 | 0 | 0 | $0 |
| Paul J Hastings | Director | June 16, 2025 A | · | 0 | 0 | $0 |
| Lota S. Zoth | Director | June 16, 2025 A | · | 0 | 0 | $0 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10% owner | April 22, 2024 S | 3,036,153 | 0 | 0 | $0 |
| Lumira Capital Investment Management Inc. | 10% owner | Feb. 20, 2024 A | 238,851 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ENGN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
7 analysts · 2026-09-29Mean target $3.29 +69.4%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.